Global Kidney Cancer Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 6.30 Million |
 Market Size (Forecast Year) |
USD 9.90 Million |
 CAGR |
% |
| Major Markets Players |
|
>全球肾癌药物市场，按类型（肾细胞癌 (RCC)、乳头状肾细胞癌、嫌色性肾细胞癌、未分类的肾细胞癌、移行细胞癌、肾母细胞瘤 (肾母细胞瘤)、肾肉瘤、血管平滑肌脂肪瘤、嗜酸细胞瘤等）、药物类别（单克隆抗体、mTOR 抑制剂、免疫检查点抑制剂、联合疗法、白细胞介素-2、α-干扰素等）、药物类型（品牌、仿制药）、最终用户（医院、家庭护理、专科诊所、其他）、分销渠道（医院药房、网上药房、零售药房）划分 - 行业趋势和预测到 2030 年。
肾癌药物市场分析及规模
预计肾癌药物市场将在预测期内出现大幅增长。全球慢性肾病发病率的增加和市场的不断增长是推动该市场增长的因素。肾癌约占全球成人恶性肿瘤总数的 2.0%，占美国所有新发癌症病例的 3.8%。肾病病例的增加和多家制药公司研发活动的增加促进了肾癌药物市场的增长。
Data Bridge Market Research 分析了 2023-2030 年预测期内肾癌药物市场的增长率。在上述预测期内，肾癌药物市场的预期复合年增长率趋于 5.90% 左右。2022 年市场价值为 630 万美元，到 2030 年将增长至 990 万美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。
肾癌药物市场范围和细分
|
报告指标 |
细节 |
|
预测期 |
2023 至 2030 年 |
|
基准年 |
2022 |
|
历史岁月 |
2021（可定制为 2015 - 2020） |
|
定量单位 |
收入（百万美元）、销量（单位）、定价（美元） |
|
涵盖的领域 |
类型（肾细胞癌(RCC)、乳头状肾细胞癌、嫌色性肾细胞癌、未分类的肾细胞癌、移行细胞癌、肾母细胞瘤（肾母细胞瘤）、肾肉瘤、血管平滑肌脂肪瘤、嗜酸细胞瘤、其他）、药物类别（单克隆抗体、mTOR 抑制剂、免疫检查点抑制剂、联合疗法、白细胞介素-2、α-干扰素、其他）、药物类型（品牌、仿制药）、最终用户（医院、家庭护理、专科诊所、其他）、分销渠道（医院药房、网上药房、零售药房） |
|
覆盖国家 |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America |
|
Market Players Covered |
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.) |
|
Market Opportunities |
|
Market Definition
Kidney cancer drugs are a great boon to patients in controlling numerous problems which cause conditions and complications during kidney diseases. It helps treat several symptoms of kidney failure such as loss of appetite, anemia, and feeling out of breath. However, kidney transplantation is considered to be the most standard treatment for advanced kidney disease. At the advanced stage of kidney cancer, where removal of the cancerous cells is essential, surgical removal of kidney is done to get cure from the disease.
Kidney Cancer Drugs Market Dynamics
Drivers
- Increased Incidence of Kidney Diseases
The increasing incidence of chronic kidney disease globally is majorly responsible for driving the growth of the kidney cancer drugs market. As per the National Kidney Foundation, around 10% of the population is majorly affected by chronic kidney disease (CKD). Renal cell carcinoma accounts for more than 90.0% of all kidney cancers while renal pelvis cancer makes up for <10.0% of microscopically confirmed kidney carcinomas. Clear cell renal cell carcinoma is the most widespread subtype of renal cell carcinoma, affecting around 70.0% of patients with RCC. This demands the increase in kidney cancer drugs.
- Increasing Demand for Immunotherapies
Increasing preference for novel immunotherapies and immune-oncologic agents will push the wide use of targeted therapies to particular patient subpopulations. Programmed death-1 (PD-1) inhibitors are meant to displace TKIs and mTOR inhibitors and work as the primary care in first-and second-line RCC settings. Combination regimens, especially those including PD-1 inhibitors, will be launched in the first-line setting to target major unmet needs, improve progression-free survival, overcome tumor resistance, and maintain the quality of life. Thus, this treatment type is enhancing the market growth.
Opportunities
- Higher Trend of Drug Approvals
The rising approval from the FDA and other authorities for the kidney cancer drugs creates several opportunities for the market growth. For instance, Marck Sharp and Dohme Corp. got approval from Food and Drug Administration (FDA) for KEYTRUDA for the treatment of patients suffering from kidney cancer cell carcinoma. Therefore, all these factors enhance the market expansion.
- Increasing Healthcare Expenditure
The rising expenditure that several organizations are funding lead to the growth of the market. For instance, China offers strong opportunities for market expansion because of the ongoing Healthy China 2020 healthcare reform and the removal of price caps on all medicine categories. The Chinese government has started a supportive 12th Five-Year Plan measures which targets biotechnology as a vital development sector. Moreover, the presence of a large target base with strong unmet clinical needs is expected to boost the market growth.
Restraints/Challenges
- Side Effects of Kidney cancer Drugs
The major side effects related with these kidney cancer drugs could limit the growth of the kidney cancer drugs market during the forecast period. Effects such as loss of appetite, fever, rashes, can impede the market growth.
- High Cost of Treatment
The huge expenditure associated with these agents hamper the market growth. The generic renal cancer treatments are quite expensive and thus is not affordable to many of the patients. Thus, it hampers the market growth.
This global kidney cancer drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global kidney cancer drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Kidney Cancer Drugs Market
The COVID-19 pandemic negatively impacted the market due to the reduction in R&D activities for kidney cancer drugs. For instance, per the data published by the National Center for Biotechnology Information in May 2020, the physicians were focused on developing the SARS-CoV-2 vaccine to avoid the rapid spread of the virus globally. Capacity for surgery has also been minimized as theater space and ventilators have been requisitioned to provide extra critical care capacity for COVID-19 patients. Thus, overall, COVID-19 had a major impact on the kidney cancer drugs market.
Recent Developments
- 2022 年，里贝朗普雷图医学院临床医院与百时美施贵宝和圣保罗研究基金会合作，推出用于治疗肾癌的新药 Nivolumab。Nivolumab 处于第 2 阶段临床试验阶段，该研究于 2022 年 1 月 18 日启动。
全球肾癌药物市场范围
肾癌药物市场根据类型、药物类型、药物类别、分销渠道和最终用户进行细分。这些细分市场之间的增长将帮助您分析行业中增长微弱的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。
类型
- 肾细胞癌 (RCC)
- 乳头状肾细胞癌
- 嫌色性肾细胞癌
- 未分类的肾细胞癌
- 移行细胞癌
- 威尔姆斯肿瘤（肾母细胞瘤）
- 肾肉瘤
- 血管平滑肌脂肪瘤
- 嗜酸细胞瘤
- 其他的
药物类别
药物类型
- 品牌
- 通用的
最终用户
- 医院
- 家庭护理
- 专科诊所
- 其他的
分销渠道
- 医院药房
- 网上药店
- 零售药店
肾癌药物市场区域分析/见解
对肾癌药物市场进行了分析，并按类型、药物类型、药物类别、分销渠道和最终用户提供了市场规模洞察和趋势。
肾癌药物市场报告涉及的主要国家 有：北美的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。
由于吸烟、高血压和糖尿病人口数量高，且该产品主要关键制造商广泛存在，亚太地区在整个预测期内一直见证着肾癌药物市场的最高增长。
由于医疗支出普遍增加，且治疗报销政策优惠，北美占据市场主导地位。此外，由于遗传性疾病增多，且医疗设施完善，欧洲占据第二大市场份额。
报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
竞争格局和全球肾癌药物市场份额分析
肾癌药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对肾癌药物市场的关注有关。
肾癌药物市场的主要参与者包括：
- 辉瑞公司 (美国)
- 阿斯利康（英国）
- 百时美施贵宝公司 (美国)
- Dr. Reddy's Laboratories Ltd（印度）
- Endo International plc（爱尔兰）
- 梯瓦制药工业有限公司 (以色列)
- 太阳制药工业有限公司 (印度)
- Mylan NV（美国）
- 诺华公司（瑞士）
- 鲁冰花（印度）
- Cipla Inc（印度）
- Aurobindo Pharma（印度）
- Fresenius SE & Co. KGaA（德国）
- 赛诺菲（法国）
- 武田药品工业株式会社 (日本)
- F. Hoffmann-La Roche Ltd（瑞士）
- 雅培（美国）
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
